Prosidion Limited

Pfizer Corporation

Warner-lambert Company

Other

Osi Pharmaceuticals, Inc.

Pfizer Products Inc.

Stuart Edward Bradley

Martin James Procter

Eric W Collington

Matthew C Fyfe

Thomas Martin Krulle

Gerard Hugh Thomas

Colin P Sambrook Smith

Karen Lesley Schofield

Robert John Rowley

Matthew Colin Thor Fyfe

Colin Peter Sambrook Smith

Jason Bloxham

Jonathan G Williams

John Kitchin

Joanna Victoria Geden

William Thomas Gattrell

Graham Michael Wynne

Robert J Rowley

Peter J Murray

Peter John Murray

Donald Smyth

Colin Peter Sambrook-Smith

Vilasben Kanji Shah

Chrystelle Marie Rasamison

William Gattrell

Ana Valdesabril

Revathy Perpetua Jeevaratnam

Lisa Sarah Bertram

Alan John Stewart

Patrick Eric Hanrahan

Peter Timothy Fry

Tom Banksia Dupree

Ana Valdes

Peter John c/o Patents Department Murray

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity. 

Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders

Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes. 

G-protein coupled receptor agonists

Compounds of formula (I): R-A-V&#x2014;B&#x2014;R, wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists

Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity. 

Bicyclic aryl and heteroaryl receptor modulators

Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth. 

Pyrrolopyridine-2-carboxylic acid hydrazides

The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Resorcinol derivatives

The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.

Process for preparing resorcinol derivatives

Growing community of inventors

Birmingham, United Kingdom

Stuart Edward Bradley